AgomAb Therapeutics (AGMB)
Develops organ-restricted ALK5 inhibitors for fibro-inflammatory diseases.
$13.60
At close+0.06 (+0.44%)
Something off on this page? Send us feedback.
EPSReportedEstimate
—————Apr '26Jun '26Aug '26
Reported—————−$0.56−$0.45−$0.91
Estimate—————−$0.52−$0.42$1.18
Surprise—————−9.1%−6.8%−177.4%
RevenueReportedEstimate
—————Apr '26Jun '26Aug '26
Reported————————
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | $1.18 | −$0.91 | −177.4% |
| Jun 2026 | −$0.42 | −$0.45 | −6.8% |
| Apr 2026 | −$0.52 | −$0.56 | −9.1% |
| Feb 2026 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | $1.18 | −$0.91 | −177.4% | — | — | — | −5.7% |
| Jun 3, 2026 | −$0.42 | −$0.45 | −6.8% | — | — | — | −0.9% |
| Apr 23, 2026 | −$0.52 | −$0.56 | −9.1% | — | — | — | +3.3% |
| Feb 25, 2026 | — | — | — | — | — | — | — |